Overview:
A variety of life-threatening & chronic disorders such as hematological diseases, immune deficiencies, genetic diseases, neurological disorders among others are treated with plasma proteins. The different clinical responses of plasma proteins are due to its unique biochemical profile, and variances in production & processing technologies. Recent developments observed in plasma protein therapeutics industry are satisfactory and ground breaking, especially recently approved recombinant protein therapeutics which caters several clinical indications such as autoimmune diseases, cancers, infectious diseases and genetic disorders. These developments in plasma protein therapeutics technologies have allowed industry players to use maximum potential of proteins in therapeutics by equivalently maintaining product safety and efficacy. The key factors driving this market are huge applications of immunoglobulins and albumin, catering wide range of diseases, rising investment in research and development of novel plasma protein-based drugs and increasing off-label use of immunoglobulins.
Global regulatory framework is evolving day by day with incessant development of novel technologies in biopharmaceutical industry. In case of plasma protein therapeutics improved versions of current therapies are being introduced that are mainly attained through enhanced drug targeting and enhancement in functionality and potency. Thus, plasma protein therapeutics market is expected to experience tremendous growth in the near future.
North America was observed as the largest plasma protein therapeutics market due rising prevalence of chronic diseases, high acceptance & accessibility towards novel drug therapy, and mounting investments in R&D of plasma proteins therapeutics. Asia Pacific was observed as the fastest growing plasma protein therapeutics market due to rising demand for novel therapeutics, developing healthcare infrastructure, and rising prevalence of cancer and autoimmune diseases.
New plasma-derived therapies entering market is on rise which is the major factor assisting the overall market growth. On the other hand, major market restraints include stringent regulatory policies, evolving reimbursement policies for developing plasma protein therapeutics industry, and intricacy in manufacturing.
The plasma protein therapeutics market is segmented on the following bases:
- Product
- Immunoglobulins
- Albumin
- Coagulation Factors
- Alpha-1 Proteinase Inhibitor
- Others (C1-esterase Inhibitors & Hyperimmune Globulins)
- Pipeline Analysis
- Phase III Drugs Analysis, Forecast till 2026
- Phase II & Phase I (Tabular Representation)
- Application
- Hemophilia
- Primary Immunodeficiency Disorder
- Idiopathic Thrombocytopenic Purpura
- Secondary Immunodeficiency
- Others (Kawasaki Disease, Hereditary Angioedema, GBS, and CIDP)
- Geography
- North America
- Europe
- United Kingdom
- Germany
- Rest of Europe
- Asia Pacific
- Japan
- China
- Rest of Asia Pacific
- Latin America
- Brazil
- Mexico
- Rest of Latin America
- Middle East and Africa
- GCC
- Rest of Middle East and Africa
Key players identified for plasma protein therapeutics market includes:
Baxter International, GRIFOLS, S.A., Biotest, CSL Behring, Kedrion, Shire Plc. Octapharma USA, Inc., Telecris, and China Biologics.
This report offers:
- Market assessment is done by furnishing the market size and compounded annual growth rate considering 2017 as the base year and period from 2018 to 2026 as the forecast period
- For the geography, product, and application segments, attractive investment proposition is given which helps biopharmaceutical manufacturers to contemplate useful financial decisions
- Competitive landscape helps in determining the competitive milieu currently existing in the plasma protein therapeutics market
- Financial health of leading players is considered in the financial information segment and diverse range of plasma proteins are covered in the product portfolio section. Recent news coverage keeps us informed regarding the latest strategic developments and their impact on the plasma protein therapeutics market.
